Bordeaux, France, Cambridge (MA), USA / October 20th, 2022 – TreeFrog Therapeutics, a biotechnology company aimed at making safer, more efficient and more affordable cell therapies based on induced pluripotent stem cells (iPSCs), today announced that an international team composed of 3 PhD students from King’s College London has been awarded the Stem Cell SpaceShot grant. With this $100,000 research funding, Matthew Wai Heng CHUNG, Cher Shen KIAR & Sofia SYNTAKA will explore the reprogramming of stem cell-derived macrophages, with the aim of repairing neuronal damage, such as spinal cord injury. [Read more…]
Greenstone Bio Secures $1.3M from CIRM for iPSC-derived Cardiovascular Cell Technologies
CIRM awards $1.3M to Greenstone Bio for stem cell research involving iPSC-derived cardiovascular cells accelerated by artificial intelligence and machine learning.
Palo Alto, CA, Oct 04, 2022 – Greenstone Biosciences, Inc. (“Greenstone Bio”), a commercial-stage computational biology company, announces that the Company has received a DISC0 grant funding from the California Institute of Regenerative Medicine (CIRM). [Read more…]
Americord® Releases Exosomes Banking with CryoMaxx™ Processing
Americord Registry announces the addition of exosome banking to their suite services, becoming the first company in the United States to do so.
NEW YORK, NEW YORK, US, October 11, 2022 – Americord Registry®, a leader in the cord blood industry, announced the addition of exosome banking to their suite of family-focused services, becoming the first private biobanking company in the United States to do so. Exosomes are tiny, extracellular vesicles that initiate cell-to-cell communication by shuttling cellular components to other cells. Pre-clinical research has shown that exosomes may regulate immune responses, wound healing, and cell growth and development. [Read more…]
TreeFrog Therapeutics moves to GMP manufacturing with cell encapsulation device delivered by Invetech
Bordeaux, France / October 11th, 2022 – TreeFrog Therapeutics, a biotechnology company developing stem cell-derived therapies in regenerative medicine and immuno-oncology based on the biomimetic C-Stem™ technology platform, and Invetech, a global leader in the development and production of automated manufacturing solutions for cell and advanced therapies, today announced the delivery of a GMP-grade cell encapsulation device using the C-Stem™ technology. [Read more…]
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
4 October 2022, YOKOHAMA, Japan – REPROCELL Inc. and San Antonio, Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. The agreement will expand REPROCELL’s global biomanufacturing service using induced pluripotent stem cells for the clinical and therapeutic purposes of its clients.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 74
- Next Page »
